Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 10/20 | 0.67 |
| ▸ | FLT3 | P36888 | 7/20 | 0.67 |
| ▸ | KDR | P35968 | 5/20 | 0.67 |
| ▸ | CSF1R | P07333 | 8/20 | 0.62 |
| ▸ | FLT4 | P35916 | 2/20 | 0.53 |
| ▸ | MET | P08581 | 8/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172536 | 0.90 | KDR (0.81) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL4499643 | 0.90 | PDGFRB (0.65) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL4215989 | 0.90 | PDGFRB (0.64) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL5598429 | 0.83 | PDGFRB (0.65) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL2174860 | 0.81 | MET (0.63) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL2173226 | 0.80 | FLT3 (0.51) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL2173131 | 0.80 | MET (0.64) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL2177267 | 0.80 | PDGFRB (0.83) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL4214384 | 0.80 | PDGFRB (0.77) | PDGFRBFLT3KDRCSF1RFLT4 | |
| SCHEMBL5598197 | 0.78 | PDGFRB (0.59) | PDGFRBFLT3KDRCSF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | PDGFRB 2155/4885FLT3 251/4885KDR 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.